One (7.7%) patient had a tumor that was hormone receptor (HR)–positive and human epidermal growth factor receptor 2 (HER2)–positive, 9 (69.2%) HR-positive and HER2-negative, 2 (15.4%) triple negative, and 1 (7.7%) with unknown HR and HER2 status. The gene discussed is ERBB2; the disease is neoplasm.